Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
08:15am, Thursday, 13'th Nov 2025
NEW YORK , Nov. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVm
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
08:00am, Thursday, 13'th Nov 2025
Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent (LOI) to license groundbreaking endoscopi
Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript
02:41pm, Wednesday, 12'th Nov 2025
Lucid Diagnostics Inc. ( LUCD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Matthew Riley - Director of Investor Relations Lishan Aklog - Chairman & CEO Dennis McGrath - C
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
10:16am, Wednesday, 12'th Nov 2025
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
08:00am, Wednesday, 12'th Nov 2025
Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimburseme
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
08:01am, Thursday, 30'th Oct 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
08:01am, Wednesday, 29'th Oct 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention
What Makes Lucid Diagnostics Inc. (LUCD) a Strong Momentum Stock: Buy Now?
01:01pm, Thursday, 16'th Oct 2025
Does Lucid Diagnostics Inc. (LUCD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
08:01am, Wednesday, 15'th Oct 2025
NEW YORK , Oct. 15, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVm
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
08:01am, Thursday, 25'th Sep 2025
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK , Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
08:01am, Tuesday, 16'th Sep 2025
Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage ex
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
09:17am, Thursday, 11'th Sep 2025
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVm
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
08:00am, Wednesday, 10'th Sep 2025
NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PA
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 09'th Sep 2025
NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAV
Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript)
04:31pm, Monday, 08'th Sep 2025
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Investor Conference Call Company Participants Matthew Riley - Director of Investor Relations Lishan Aklog - Chairman & CEO Dennis McGrath - Chief Financial Office
